<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Arch Med Sci</journal-id><journal-id journal-id-type="publisher-id">AMS</journal-id><journal-title-group><journal-title>Archives of Medical Science : AMS</journal-title></journal-title-group><issn pub-type="ppub">1734-1922</issn><issn pub-type="epub">1896-9151</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23515108</article-id><article-id pub-id-type="pmc">3598137</article-id><article-id pub-id-type="publisher-id">20282</article-id><article-id pub-id-type="doi">10.5114/aoms.2013.33357</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-&#x003b3; activating capacity on plasma 8-isoprostane prostaglandin F<sub>2a</sub> levels</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rizos</surname><given-names>Christos V.</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Liberopoulos</surname><given-names>Evangelos N.</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Tellis</surname><given-names>Constantinos C.</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Tselepis</surname><given-names>Alexandros D.</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Elisaf</surname><given-names>Moses S.</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Department of Internal Medicine, School of Medicine, University of Ioannina, Greece</aff><aff id="AF0002"><label>2</label>Laboratory of Biochemistry, School of Chemistry, University of Ioannina, Greece</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Prof. Moses S. Elisaf MD, FASA, FRSH, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45 110, Greece. Phone: +30 26510 07509. Fax: +30 26510 07016. E-mail: <email xlink:href="egepi@cc.uoi.gr">egepi@cc.uoi.gr</email>, <email xlink:href="vaglimp@yahoo.com">vaglimp@yahoo.com</email>, <email xlink:href="xristos10@gmail.com">xristos10@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>2</month><year>2013</year></pub-date><pub-date pub-type="ppub"><day>21</day><month>2</month><year>2013</year></pub-date><volume>9</volume><issue>1</issue><fpage>172</fpage><lpage>176</lpage><history><date date-type="received"><day>08</day><month>8</month><year>2012</year></date><date date-type="rev-recd"><day>06</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>21</day><month>9</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Termedia &#x00026; Banach</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Introduction</title><p>Oxidative stress is associated with the development and progression of cardiovascular disease. Plasma 8-isoprostane prostaglandin F<sub>2a</sub> (8-iso-PGF<sub>2a</sub>) levels are a reliable marker of oxidative stress.</p></sec><sec id="st2"><title>Material and methods</title><p>Patients (<italic>n</italic> = 151) with hypertension, dyslipidemia and impaired fasting glucose were randomly allocated to rosuvastatin (10 mg/day) plus telmisartan 80 mg/day (RT group, <italic>n</italic> = 52) or irbesartan 300 mg/day (RI group, <italic>n</italic> = 48) or olmesartan 20 mg/day (RO group, <italic>n</italic> = 51). After 6 months of treatment, changes in plasma 8-iso-PGF<sub>2a</sub> levels were blindly evaluated.</p></sec><sec id="st3"><title>Results</title><p>A decrease of 8-iso-PGF<sub>2a</sub> levels vs baseline was observed only in the RT group (&#x02013;8.6%; <italic>p</italic> = 0.02). A trend for decrease vs. baseline was observed in the RI (&#x02013;5.7%; <italic>p</italic> = 0.40) and RO (&#x02013;3.7%; <italic>p</italic> = 0.60) groups. Changes of 8-iso-PGF<sub>2a</sub> levels between groups were not significantly different (<italic>p</italic> = 0.70).</p></sec><sec id="st4"><title>Conclusions</title><p>The combination of rosuvastatin with sartans of different peroxisome proliferator receptor-&#x003b3; activating capacity was associated with a decrease in levels of plasma 8-iso-PGF<sub>2a</sub>. This decrease reached significance only in the telmisartan group.</p></sec></abstract><kwd-group><kwd>rosuvastatin</kwd><kwd>telmisartan</kwd><kwd>olmesartan</kwd><kwd>irbesartan</kwd><kwd>oxidative stress</kwd></kwd-group></article-meta></front><body><sec id="S0001"><title>Introduction</title><p>Hypercholesterolemia and high blood pressure are at the cornerstone of cardiovascular disease (CVD) development and progression and often coexist. In the context of comprehensive management [<xref ref-type="bibr" rid="CIT0001">1</xref>, <xref ref-type="bibr" rid="CIT0002">2</xref>], the combination of a statin with an angiotensin receptor blocker (ARB) is common. Oxidative stress plays an important role in the pathogenesis and development of CVD [<xref ref-type="bibr" rid="CIT0003">3</xref>, <xref ref-type="bibr" rid="CIT0004">4</xref>]. The isoprostanes are a family of eicosanoids of non-enzymatic origin produced by the random oxidation of tissue phospholipids by oxygen radicals. Levels of 8-isoprostane prostaglandin F<sub>2a</sub> (8-iso-PGF<sub>2a</sub>) have been established as a reliable marker of oxidative stress [<xref ref-type="bibr" rid="CIT0005">5</xref>&#x02013;<xref ref-type="bibr" rid="CIT0007">7</xref>] and coronary heart disease [<xref ref-type="bibr" rid="CIT0008">8</xref>]. Statins have a favorable or neutral effect on oxidative stress markers [<xref ref-type="bibr" rid="CIT0009">9</xref>, <xref ref-type="bibr" rid="CIT0010">10</xref>]. The peroxisome proliferator receptor &#x003b3; (PPAR-&#x003b3;) modifies the expression of numerous metabolic related genes and could therefore play a role in oxidative stress. Thiazolidinediones have been shown to hold antioxidative pleiotropic effects beyond glucose lowering [<xref ref-type="bibr" rid="CIT0011">11</xref>, <xref ref-type="bibr" rid="CIT0012">12</xref>]. Some ARBs, mainly telmisartan and to a lesser degree irbesartan, have the ability to partially activate PPAR-&#x003b3; [<xref ref-type="bibr" rid="CIT0013">13</xref>]. This trait of some ARBs may differentiate their effect on oxidative stress.</p><p>The present study evaluated the effects of combining a statin with ARBs of different capacity to activate PPAR-&#x003b3; on plasma 8-iso-PGF<sub>2a</sub> levels.</p></sec><sec sec-type="materials|methods" id="S0002"><title>Material and methods</title><sec id="S20003"><title>Subjects</title><p>This is a pre-specified analysis of a previously reported study [<xref ref-type="bibr" rid="CIT0014">14</xref>]. In brief, patients attending the Outpatient Lipid Clinic of the University Hospital of Ioannina, Greece were recruited. Eligible patients were those with impaired fasting plasma glucose, mixed dyslipidemia and stage 1 hypertension. Patients were excluded if they had any of the following: (1) history of diabetes, (2) history of CVD, (3) elevated triglycerides (TG) (&#x0003e; 400 mg/ dl; 4.52 mmol/l), (4) kidney disease, (5) hypothyroidism, (6) liver dysfunction, (7) receiving lipid-lowering or antihypertensive treatment in the last 3 months prior to recruitment and (8) females who did not take sufficient contraceptive measures.</p><p>All participants gave written informed consent and the study protocol was approved by our institutional ethics committee.</p></sec><sec id="S20004"><title>Study design</title><p>All patients (<italic>n</italic> = 159) received a 12-week dietary intervention in accordance with the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines and the Dietary Approaches to Stop Hypertension (DASH) diet [<xref ref-type="bibr" rid="CIT0015">15</xref>]. Patients (<italic>n</italic> = 151) who continued to meet the inclusion criteria after the dietary intervention period were randomly allocated to open-label: i) rosuvastatin (10 mg/day) plus a sartan with partial PPAR-&#x003b3; activating capacity (telmisartan 80 mg/day; <italic>n</italic> = 52; RT group), ii) rosuvastatin (10 mg/day) plus a sartan with weak partial PPAR-&#x003b3; activating capacity (irbesartan 300 mg/day; <italic>n</italic> = 48; RI group) or iii) rosuvastatin (10 mg/day) plus a sartan without PPAR-&#x003b3; activating capacity (olmesartan 20 mg/day; <italic>n</italic> = 51; RO group).</p><p>Selected doses of studied drugs are the usual starting doses in clinical practice in our country. Moreover, selected sartan doses are equivalent in terms of blood-pressure lowering.</p><p>Compliance with study medication was assessed at week 24 by counting taken tablets; patients were considered compliant if they took 80-100% of the prescribed number of tablets.</p></sec><sec id="S20005"><title>Biochemical parameters</title><p>All laboratory determinations were carried out after an overnight fast as previously described [<xref ref-type="bibr" rid="CIT0014">14</xref>] at baseline (which was after the 12-week dietary intervention) and at 6 months after initiation of treatment. Laboratory determinations were performed blindly with regard to treatment allocation. Plasma levels of 8-iso-PGF<sub>2a</sub> were determined by means of a competitive ELISA using a commercially available kit (Cayman Chemicals, Ann Arbor, MI) [<xref ref-type="bibr" rid="CIT0016">16</xref>].</p></sec><sec id="S20006"><title>Statistical analysis</title><p>Values are given as mean &#x000b1; standard deviation (SD) and median (range) for parametric and non-parametric data, respectively. Continuous variables were tested for lack of normality by the Kolmogorov-Smirnov test and logarithmic transformations were accordingly performed for non-parametric variables. The paired-sample <italic>t</italic>-test was used for assessing the effect of treatment in each group. Analysis of covariance (ANCOVA), adjusted for baseline values, was used for comparisons between treatment groups. Significance was defined as <italic>p</italic> &#x0003c; 0.05. Analyses were performed using the Statistical Package for the Social Sciences (SPSS) 15.0 (SPSS Inc, Chicago, IL). In a post hoc calculation, given the effect size, the alpha level, and the sample size, we calculate that the achieved power of this pre-specified analysis to find a significant difference for the 8-iso-PGF<sub>2a</sub> was above 95%.</p></sec></sec><sec sec-type="results" id="S0007"><title>Results</title><p>A total of 159 patients (76 males, mean age 60 years) were enrolled. Of them, 151 (73 males, mean age 60 years) continued to meet the inclusion criteria after the dietary intervention period and were randomized to the 3 groups. No patient dropped out and compliance was &#x0003e; 80% in all patients. No significant differences regarding baseline data were found across groups (<xref ref-type="table" rid="T0001">Table I</xref>). The effects of all combinations on metabolic parameters have been previously described [<xref ref-type="bibr" rid="CIT0014">14</xref>]. In brief, after the study end no differentiation in anthropometric variables and blood pressure was observed between groups. In addition, lipid profile was similarly altered in all groups (<xref ref-type="table" rid="T0002">Table II</xref>). However, the homeostasis model assessment insulin resistance (HOMA-IR) decreased only in the RT group while an increase was observed in the other 2 regimens (<xref ref-type="table" rid="T0002">Table II</xref>).
</p><table-wrap id="T0001" position="float"><label>Table I</label><caption><p>Baseline demographic characteristics of study participants<xref ref-type="table-fn" rid="TF0001">*</xref>
</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">RT group (<italic>n</italic> = 52)</th><th align="center" rowspan="1" colspan="1">RI group (<italic>n</italic> = 48)</th><th align="center" rowspan="1" colspan="1">RO group (<italic>n</italic> = 51)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N (females/males)</td><td align="center" rowspan="1" colspan="1">25/27</td><td align="center" rowspan="1" colspan="1">26/22</td><td align="center" rowspan="1" colspan="1">27/24</td></tr><tr><td align="left" rowspan="1" colspan="1">Age [years]</td><td align="center" rowspan="1" colspan="1">60 &#x000b1;10</td><td align="center" rowspan="1" colspan="1">60 &#x000b1;10</td><td align="center" rowspan="1" colspan="1">58 &#x000b1;12</td></tr><tr><td align="left" rowspan="1" colspan="1">Smokers [%]</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index [kg/m2]</td><td align="center" rowspan="1" colspan="1">29 &#x000b1;4</td><td align="center" rowspan="1" colspan="1">29 &#x000b1;5</td><td align="center" rowspan="1" colspan="1">28 &#x000b1;4</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference [cm]</td><td align="center" rowspan="1" colspan="1">101 &#x000b1;9</td><td align="center" rowspan="1" colspan="1">101 &#x000b1;11</td><td align="center" rowspan="1" colspan="1">100 &#x000b1;8</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure [mm Hg]</td><td align="center" rowspan="1" colspan="1">153 &#x000b1;14</td><td align="center" rowspan="1" colspan="1">152 &#x000b1;11</td><td align="center" rowspan="1" colspan="1">151 &#x000b1;11</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure [mm Hg]</td><td align="center" rowspan="1" colspan="1">91 &#x000b1;10</td><td align="center" rowspan="1" colspan="1">90 &#x000b1;9</td><td align="center" rowspan="1" colspan="1">93 &#x000b1;8</td></tr></tbody></table><table-wrap-foot><fn><p>RT &#x02013; rosuvastatin + telmisartan, RI &#x02013; rosuvastatin + irbesartan, RO &#x02013; rosuvastatin + olmesartan, NS &#x02013; not significant.</p></fn><fn id="TF0001"><label>*</label><p>Values are expressed as mean &#x000b1; SD; p = NS for all comparisons</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" position="float"><label>Table II</label><caption><p>Serum metabolic parameters at baseline and after 6 months of treatment<xref ref-type="table-fn" rid="TF0002">*</xref>
</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Baseline<xref ref-type="table-fn" rid="TF0002">*</xref>
</th><th align="center" rowspan="1" colspan="1">6 months<xref ref-type="table-fn" rid="TF0002">*</xref>
</th><th align="center" rowspan="1" colspan="1">Change [%]</th></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">
<bold>Total cholesterol [mg/dl (mmol/l)]</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RT Group</td><td align="center" rowspan="1" colspan="1">271 &#x000b1;29 (7.0 &#x000b1;0.8)</td><td align="center" rowspan="1" colspan="1">177 &#x000b1;28 (4.6 &#x000b1;0.7)</td><td align="center" rowspan="1" colspan="1">&#x02013;35<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RI Group</td><td align="center" rowspan="1" colspan="1">269 &#x000b1;23 (7.0 &#x000b1;0.6)</td><td align="center" rowspan="1" colspan="1">170 &#x000b1;30 (4.4 &#x000b1;0.8)</td><td align="center" rowspan="1" colspan="1">&#x02013;37<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RO Group</td><td align="center" rowspan="1" colspan="1">274 &#x000b1;27 (7.0 &#x000b1;0.7)</td><td align="center" rowspan="1" colspan="1">175 &#x000b1;32 (4.5 &#x000b1;0.8)</td><td align="center" rowspan="1" colspan="1">&#x02013;36<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>Triglycerides [mg/dl (mmol/l)]</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RT Group</td><td align="center" rowspan="1" colspan="1">180 (152-290) [2.0 (1.7-3.3)]</td><td align="center" rowspan="1" colspan="1">135 (81-270) [1.5 (0.9-3.1)]</td><td align="center" rowspan="1" colspan="1">&#x02013;25<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RI Group</td><td align="center" rowspan="1" colspan="1">173 (151-276) [3.3 (1.7-3.1)]</td><td align="center" rowspan="1" colspan="1">125 (77-252) [1.4 (0.9-2.9)]</td><td align="center" rowspan="1" colspan="1">&#x02013;28<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RO Group</td><td align="center" rowspan="1" colspan="1">187 (153-289) [2.1 (1.7-3.3)]</td><td align="center" rowspan="1" colspan="1">147 (76-210) [0.9 (1.7-2.4)]</td><td align="center" rowspan="1" colspan="1">&#x02013;23<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>HDL-C [mg/dl (mmol/l)]</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RT Group</td><td align="center" rowspan="1" colspan="1">55 &#x000b1;7 (1.4 &#x000b1;0.2)</td><td align="center" rowspan="1" colspan="1">56 &#x000b1;7 (1.4 &#x000b1;0.2)</td><td align="center" rowspan="1" colspan="1">+1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RI Group</td><td align="center" rowspan="1" colspan="1">58 &#x000b1;11 (1.5 &#x000b1;0.3)</td><td align="center" rowspan="1" colspan="1">59 &#x000b1;15 (1.5 &#x000b1;0.4)</td><td align="center" rowspan="1" colspan="1">+1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RO Group</td><td align="center" rowspan="1" colspan="1">53 &#x000b1;9 (1.4 &#x000b1;0.2)</td><td align="center" rowspan="1" colspan="1">54 &#x000b1;10 (1.3 &#x000b1;0.3)</td><td align="center" rowspan="1" colspan="1">+2</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>LDL-C [mg/dl (mmol/l)]</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RT Group</td><td align="center" rowspan="1" colspan="1">182 &#x000b1;23 (4.7 &#x000b1;0.6)</td><td align="center" rowspan="1" colspan="1">105 &#x000b1;28 (2.7 &#x000b1;0.7)</td><td align="center" rowspan="1" colspan="1">&#x02013;42<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RI Group</td><td align="center" rowspan="1" colspan="1">176 &#x000b1;23 (4.6 &#x000b1;0.6)</td><td align="center" rowspan="1" colspan="1">99 &#x000b1;22 (2.6 &#x000b1;0.6)</td><td align="center" rowspan="1" colspan="1">&#x02013;44<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RO Group</td><td align="center" rowspan="1" colspan="1">183 &#x000b1;22 (4.7 &#x000b1;0.6)</td><td align="center" rowspan="1" colspan="1">99 &#x000b1;31 (2.6 &#x000b1;0.8)</td><td align="center" rowspan="1" colspan="1">&#x02013;46<xref ref-type="table-fn" rid="TF0004">&#x02021;</xref>
</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>Fasting plasma glucose [mg/dl (mmol/l)]</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RT Group</td><td align="center" rowspan="1" colspan="1">112 &#x000b1;10 (6.2 &#x000b1;0.6)</td><td align="center" rowspan="1" colspan="1">113 &#x000b1;9 (6.3 &#x000b1;0.5)</td><td align="center" rowspan="1" colspan="1">+1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RI Group</td><td align="center" rowspan="1" colspan="1">110 &#x000b1;10 (6.1 &#x000b1;0.6)</td><td align="center" rowspan="1" colspan="1">112 &#x000b1;7 (6.2 &#x000b1;0.4)</td><td align="center" rowspan="1" colspan="1">+1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RO Group</td><td align="center" rowspan="1" colspan="1">114 &#x000b1;11 (6.3 &#x000b1;0.6)</td><td align="center" rowspan="1" colspan="1">114 &#x000b1;8 (6.3 &#x000b1;0.4)</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>HOMA-IR</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RT Group</td><td align="center" rowspan="1" colspan="1">2.6 (0.6-6.6)</td><td align="center" rowspan="1" colspan="1">1.8 (0.5-5.1)</td><td align="center" rowspan="1" colspan="1">&#x02013;29<xref ref-type="table-fn" rid="TF0003">&#x02020;</xref>
<xref ref-type="table-fn" rid="TF0005">&#x000b6;</xref>
<xref ref-type="table-fn" rid="TF0006">&#x000a7;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RI Group</td><td align="center" rowspan="1" colspan="1">2.5 (0.5-6.2)</td><td align="center" rowspan="1" colspan="1">2.9 (0.5-8.1)</td><td align="center" rowspan="1" colspan="1">+16<xref ref-type="table-fn" rid="TF0003">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RO Group</td><td align="center" rowspan="1" colspan="1">2.4 (0.5-7.9)</td><td align="center" rowspan="1" colspan="1">2.7 (0.5-5.2)</td><td align="center" rowspan="1" colspan="1">+14<xref ref-type="table-fn" rid="TF0003">&#x02020;</xref>
</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>8-iso-PGF<sub>2a</sub> [pg/ml]</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RT Group</td><td align="center" rowspan="1" colspan="1">57.6 (26.0-91.0)</td><td align="center" rowspan="1" colspan="1">52.7 (25.1-88.6)</td><td align="center" rowspan="1" colspan="1">&#x02013;8.6<xref ref-type="table-fn" rid="TF0003">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RI Group</td><td align="center" rowspan="1" colspan="1">51.8 (25.3-88.2)</td><td align="center" rowspan="1" colspan="1">48.9 (26.0-87.8)</td><td align="center" rowspan="1" colspan="1">&#x02013;5.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RO Group</td><td align="center" rowspan="1" colspan="1">54.3 (21.7-96.6)</td><td align="center" rowspan="1" colspan="1">52.3 (21.9-102.5)</td><td align="center" rowspan="1" colspan="1">&#x02013;3.7</td></tr></tbody></table><table-wrap-foot><fn><p>RT &#x02013; rosuvastatin + telmisartan, RI &#x02013; rosuvastatin + irbesartan, RO &#x02013; rosuvastatin + olmesartan, HDL-C &#x02013; high-density lipoprotein cholesterol, LDL-C &#x02013; low-density lipoprotein cholesterol, HOMA-IR &#x02013; homeostasis model assessment insulin resistance, 8-iso-PGF<sub>2a</sub> &#x02013; isoprostane 8-iso-prostaglandin F<sub>2a</sub>.</p></fn><fn id="TF0002"><label>*</label><p>Values are expressed as mean &#x000b1; SD (except for triglycerides, HOMA-IR and 8-iso-PGF<sub>2a</sub>, which are expressed as median (range)).</p></fn><fn id="TF0003"><label>&#x02020;</label><p>p &#x0003c; 0.05 vs. baseline</p></fn><fn id="TF0004"><label>&#x02021;</label><p>p &#x0003c; 0.001 vs. baseline</p></fn><fn id="TF0005"><label>&#x000b6;</label><p>p &#x0003c; 0.01 vs. RI group</p></fn><fn id="TF0006"><label>&#x000a7;</label><p>p &#x0003c; 0.05 vs. RO group</p></fn></table-wrap-foot></table-wrap><p>Plasma levels of 8-iso-PGF<sub>2a</sub> vs. baseline decreased significantly only in the RT group (&#x02013;8.6%; <italic>p</italic> = 0.02) (<xref ref-type="table" rid="T0002">Table II</xref>). A non-significant trend for decrease vs. baseline was observed in the RI (&#x02013;5.7%; <italic>p</italic> = 0.40) and RO (&#x02013;3.7%; <italic>p</italic> = 0.60) groups (<xref ref-type="table" rid="T0002">Table II</xref>). The changes of plasma 8-iso-PGF<sub>2a</sub> levels between groups were not significantly different (<italic>p</italic> = 0.70).</p></sec><sec sec-type="discussion" id="S0008"><title>Discussion</title><p>The combination of rosuvastatin with sartans of different PPAR-&#x003b3; activating capacity was associated with a decrease in levels of plasma 8-iso-PGF<sub>2a</sub>. However, this decrease reached significance only in the telmisartan group.</p><p>Statins have been shown to have either a beneficial or neutral effect on oxidative stress markers. Fluvastatin was shown to possess antioxidant properties [<xref ref-type="bibr" rid="CIT0009">9</xref>], rosuvastatin was associated with only a trend for decreasing oxidative stress [<xref ref-type="bibr" rid="CIT0010">10</xref>], while atorvastatin showed a neutral effect on oxidative status [<xref ref-type="bibr" rid="CIT0017">17</xref>]. The activation of the renin-angiotensin system (RAS) has been shown to promote oxidative stress [<xref ref-type="bibr" rid="CIT0018">18</xref>, <xref ref-type="bibr" rid="CIT0019">19</xref>]. As a result, ARBs may have beneficial effects on oxidative stress. Indeed, irbesartan [<xref ref-type="bibr" rid="CIT0020">20</xref>] and olmesartan [<xref ref-type="bibr" rid="CIT0021">21</xref>] have been associated with a decrease in oxidative stress markers, while eprosartan was not associated with any changes of 8-iso-PGF<sub>2a</sub> plasma levels [<xref ref-type="bibr" rid="CIT0022">22</xref>]. Telmisartan was shown to decrease markers of oxidative stress vs. valsartan in type 2 diabetic patients with nephropathy [<xref ref-type="bibr" rid="CIT0023">23</xref>].</p><p>Thiazolidinediones (TZDs), by activating PPAR-&#x003b3;, increase insulin sensitivity. Thiazolidinediones have been shown to hold antioxidative effects beyond glucose lowering [<xref ref-type="bibr" rid="CIT0011">11</xref>, <xref ref-type="bibr" rid="CIT0012">12</xref>]. Telmisartan, which partially activates PPAR-&#x003b3;, may also possess additional antioxidative properties. The recent Effects of Simvastatin and Rosiglitazone Combination in patients with the metabolic syndrome (SIROCO) study showed that the combination of a statin (simvastatin) together with a PPAR-&#x003b3; agonist (rosiglitazone) decreased markers of oxidative stress [<xref ref-type="bibr" rid="CIT0024">24</xref>]. By combining a commonly used statin (rosuvastatin) with telmisartan, which partially activates PPAR-&#x003b3;, an improvement of oxidative stress markers may be expected.</p><p>Indeed, a significant decrease in 8-iso-PGF<sub>2a</sub> was seen only in the rosuvastatin/telmisartan group in this study. Although all ARBs may have to some degree antioxidative effects, telmisartan may possess additional such effects since it can activate the PPAR-&#x003b3; receptors. On the other hand, this decrease was not significantly different when compared with the changes of 8-iso-PGF<sub>2a</sub> in the other 2 groups. This finding puts into question whether telmisartan is indeed different compared with the other 2 sartans. It should be noted that the baseline values of 8-iso-PGF<sub>2a</sub> were not particularly increased. Indeed, baseline levels of 8-iso-PGF<sub>2a</sub> were very close to the normal levels of 8-iso-PGF<sub>2a</sub>, which our group has measured using the same method in a previous study [<xref ref-type="bibr" rid="CIT0007">7</xref>]. As a result, the potential of a drug treatment to further decrease the already near normal levels of 8-iso-PGF<sub>2a</sub> is diminished.</p><p>A limitation of our study was that no other markers of oxidative stress were determined. Another limitation was the small number of participants. Moreover, a control group receiving rosuvastatin as monotherapy was not included since it was considered unethical to further delay antihypertensive treatment in these high-risk patients. Additional limitations include the open-label design, the relatively short period of follow-up as well as the fact that no oral glucose tolerance test was performed in patients with impaired fasting glucose to identify diabetic patients.</p><p>In conclusion, the combination of rosuvastatin with sartans of different PPAR-&#x003b3; activating capacity was associated with a decrease in levels of plasma 8-iso-PGF<sub>2a</sub>. This decrease reached significance only in the telmisartan group.</p></sec></body><back><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsiki</surname><given-names>N</given-names></name><name><surname>Mikhailidis</surname><given-names>DP</given-names></name><name><surname>Athyros</surname><given-names>VG</given-names></name><name><surname>Hatzitolios</surname><given-names>AI</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Banach</surname><given-names>M</given-names></name></person-group><article-title>Are we getting to lipid targets in real life?</article-title><source>Arch Med Sci</source><year>2010</year><volume>6</volume><fpage>639</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">22419917</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athyros</surname><given-names>VG</given-names></name><name><surname>Hatzitolios</surname><given-names>AI</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><etal/></person-group><article-title>IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis</article-title><source>Arch Med Sci</source><year>2011</year><volume>7</volume><fpage>984</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22328881</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madamanchi</surname><given-names>NR</given-names></name><name><surname>Vendrov</surname><given-names>A</given-names></name><name><surname>Runge</surname><given-names>MS</given-names></name></person-group><article-title>Oxidative stress and vascular disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2005</year><volume>25</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15539615</pub-id></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassalle</surname><given-names>C</given-names></name><name><surname>Petrozzi</surname><given-names>L</given-names></name><name><surname>Botto</surname><given-names>N</given-names></name><name><surname>Andreassi</surname><given-names>MG</given-names></name><name><surname>Zucchelli</surname><given-names>GC</given-names></name></person-group><article-title>Oxidative stress and its association with coronary artery disease and different atherogenic risk factors</article-title><source>J Intern Med</source><year>2004</year><volume>256</volume><fpage>308</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15367173</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group><article-title>The isoprostanes: their quantification as an index of oxidant stress status in vivo</article-title><source>Drug Metab Rev</source><year>2000</year><volume>32</volume><fpage>377</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">11139135</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>GL</given-names></name><name><surname>Musiek</surname><given-names>ES</given-names></name><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group><article-title>F2-isoprostanes as markers of oxidative stress in vivo: an overview</article-title><source>Biomarkers</source><year>2005</year><volume>10</volume><issue>Supp l</issue><fpage>S10</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16298907</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostapanos</surname><given-names>MS</given-names></name><name><surname>Spyrou</surname><given-names>AT</given-names></name><name><surname>Tellis</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress</article-title><source>Lipids</source><year>2011</year><volume>46</volume><fpage>341</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21359598</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name><name><surname>Roberts</surname><given-names>LJ</given-names><suffix>2nd</suffix></name></person-group><article-title>F2-isoprostanes as an indicator and risk factor for coronary heart disease</article-title><source>Free Radic Biol Med</source><year>2011</year><volume>50</volume><fpage>559</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">21126576</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>MI</given-names></name><name><surname>Baykal</surname><given-names>Y</given-names></name><name><surname>Kilic</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of statins on oxidative stress</article-title><source>Biol Trace Elem Res</source><year>2004</year><volume>98</volume><fpage>119</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">15073410</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agouridis</surname><given-names>AP</given-names></name><name><surname>Tsimihodimos</surname><given-names>V</given-names></name><name><surname>Filippatos</surname><given-names>TD</given-names></name><etal/></person-group><article-title>The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia</article-title><source>Expert Opin Pharmacother</source><year>2011</year><volume>12</volume><fpage>2605</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21714585</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Da Ros</surname><given-names>R</given-names></name><name><surname>Assaloni</surname><given-names>R</given-names></name><name><surname>Ceriello</surname><given-names>A</given-names></name></person-group><article-title>The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance</article-title><source>Diabet Med</source><year>2004</year><volume>21</volume><fpage>1249</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">15498094</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Kleinhenz</surname><given-names>DJ</given-names></name><name><surname>Rupnow</surname><given-names>HL</given-names></name><etal/></person-group><article-title>The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice</article-title><source>Vascul Pharmacol</source><year>2007</year><volume>46</volume><fpage>456</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17337254</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>SC</given-names></name><name><surname>Pershadsingh</surname><given-names>HA</given-names></name><name><surname>Ho</surname><given-names>CI</given-names></name><etal/></person-group><article-title>Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity</article-title><source>Hypertension</source><year>2004</year><volume>43</volume><fpage>993</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">15007034</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizos</surname><given-names>CV</given-names></name><name><surname>Milionis</surname><given-names>HJ</given-names></name><name><surname>Kostapanos</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study</article-title><source>Clin Ther</source><year>2010</year><volume>32</volume><fpage>492</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">20399986</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Svetkey</surname><given-names>LP</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">11136953</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dounousi</surname><given-names>E</given-names></name><name><surname>Papavasiliou</surname><given-names>E</given-names></name><name><surname>Makedou</surname><given-names>A</given-names></name><etal/></person-group><article-title>Oxidative stress is progressively enhanced with advancing stages of CKD</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>48</volume><fpage>752</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">17059994</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tycinska</surname><given-names>AM</given-names></name><name><surname>Janica</surname><given-names>J</given-names></name><name><surname>Mroczko</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hypotensive effect of atorvastatin in hypertensive patients: the association among flow-mediated dilation, oxidative stress and endothelial dysfunction</article-title><source>Arch Med Sci</source><year>2011</year><volume>7</volume><fpage>955</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">22328877</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueckschloss</surname><given-names>U</given-names></name><name><surname>Quinn</surname><given-names>MT</given-names></name><name><surname>Holtz</surname><given-names>J</given-names></name><name><surname>Morawietz</surname><given-names>H</given-names></name></person-group><article-title>Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2002</year><volume>22</volume><fpage>1845</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12426214</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Dikalov</surname><given-names>S</given-names></name><etal/></person-group><article-title>Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II</article-title><source>Hypertension</source><year>2002</year><volume>40</volume><fpage>511</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12364355</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sola</surname><given-names>S</given-names></name><name><surname>Mir</surname><given-names>MQ</given-names></name><name><surname>Cheema</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>343</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15655130</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fliser</surname><given-names>D</given-names></name><name><surname>Wagner</surname><given-names>KK</given-names></name><name><surname>Loos</surname><given-names>A</given-names></name><name><surname>Tsikas</surname><given-names>D</given-names></name><name><surname>Haller</surname><given-names>H</given-names></name></person-group><article-title>Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><fpage>1135</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">15716329</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizos</surname><given-names>EC</given-names></name><name><surname>Spyrou</surname><given-names>A</given-names></name><name><surname>Liberopoulos</surname><given-names>EN</given-names></name><etal/></person-group><article-title>Effects of eprosartan on serum metabolic parameters in patients with essential hypertension</article-title><source>Open Cardiovasc Med J</source><year>2007</year><volume>1</volume><fpage>22</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18949087</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galle</surname><given-names>J</given-names></name><name><surname>Schwedhelm</surname><given-names>E</given-names></name><name><surname>Pinnetti</surname><given-names>S</given-names></name><name><surname>Boger</surname><given-names>RH</given-names></name><name><surname>Wanner</surname><given-names>C</given-names></name></person-group><article-title>Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy</article-title><source>Nephrol Dial Transplant</source><year>2008</year><volume>23</volume><fpage>3174</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">18450829</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazich</surname><given-names>I</given-names></name><name><surname>Sarafidis</surname><given-names>P</given-names></name><name><surname>de Guzman</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Oliva</surname><given-names>R</given-names></name><name><surname>Bakris</surname><given-names>G</given-names></name></person-group><article-title>Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><fpage>181</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21955403</pub-id></element-citation></ref></ref-list></back></article>